NKI actively stimulates collaboration between clinical and basic scientists, resulting in a large translational research program.
The Netherlands Cancer Institute (NKI) has been at the international forefront of cancer care and research for more than a century. The NKI is a Comprehensive Cancer Center, officially accredited by the OECI, combining a dedicated cancer hospital (Antoni van Leeuwenhoek ziekenhuis - AVL) and research institute (Het Nederlands Kanker Instituut - NKI) under one roof in an independent organization with one Board of Directors.
Combining health care and scientific research within the same institute offers a great, unique benefit for cancer patients. Specialized cancer care professionals work together daily in multidisciplinary teams to set up and carry out treatment plans tailored to the needs of individual patients, because no two tumors are alike. Cancer patients or patients referred for cancer diagnosis can come to our hospital, known as the Antoni van Leeuwenhoek, to make use of this personalized approach and the state-of-the-art research and treatment facilities.
The hospital has 180 beds, an outpatient clinic and a large radiotherapy department. Facilities for clinical research include a comprehensive patient database, a large collection of tumor samples with extensive clinical data, other biobanks, a data center for clinical studies, extensive diagnostic facilities, a pharmacy with a GMP-certified production unit for experimental drugs and biologicals, large patient cohorts, and active research groups in pharmacology, epidemiology and psychosocial oncology. The research institute has more than 650 active employees investigating many aspects of cancer development, diagnosis, treatment and epidemiology. Scientists at the Netherlands Cancer Institute have access to state-of-the-art research facilities supporting their basic, clinical and translational research.
The laboratories cover almost all major areas of cancer research, with special emphasis on genetics, mouse models, cell biology, structural biology, cell-based screens, immunology and translational research. The institute houses a large animal facility, dedicated to mouse models for cancer with units for pathology, transgenesis, imaging, and intervention, and facilities like microscopy, flow cytometry, genomics, proteomics, a high throughput screening facility for siRNA and small molecule screens, and a molecular pathology and biobanking facility. General support facilities include the IT department, accounting, procurement, HR, PR and fund raising. The Institute also houses a cancer library, a Technology Transfer Office, administrative support for the staff.
This scientific research could not be carried out without the institutional support of the Dutch Cancer Society, the Ministry of Health, Welfare and Sport, the many research grants obtained by our researchers from (inter)national funding agencies, and the generous donations made by individuals that support our research program.
For more information please visit our websites www.nki.nl and www.avl.nl.
Ruud van der Noll, PhD
Liaison officer, Contract manager
Antoni van Leeuwenhoek Ziekenhuis - Nederlands Kanker Instituut
Rene Medema, MD, PhD, is Professor of Experimental Oncology, Director of Research, and Chairman of the Board of Directors of NKI.
Emile Voest, MD, PhD, is Professor of Medical Oncology and Medical Director of the NKI.
Marien van der Meer, MSc, is NKI’s Chief Financial & Operational Officer.